RFL — Rafael Holdings, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1713863 ·
Last close
$1.60
Market Cap
$81.94M
52W High
$3.96
52W Low
$1.12
ADV30
219,007
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 179,000 | 171,000 | -6,870,000 | -4,226,000 | 91,990,000 | 30,497,000 | 11,187,000 |
| Jan 2026 | 211,000 | 199,000 | -6,655,000 | -6,417,000 | 99,315,000 | 37,779,000 | 16,057,000 |
| Oct 2025 | 240,000 | 231,000 | -10,141,000 | -9,816,000 | 105,375,000 | 45,539,000 | 16,195,000 |
| Apr 2025 | 362,000 | 322,000 | -5,913,000 | -4,779,000 | 108,096,000 | 37,936,000 | 23,578,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,803,000
Investing CF
$-7,883,000
Financing CF
$-79,000
CapEx
$-8,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.59
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-252,722,000
Inventory
$276,000
Receivables
$294,000
ST Investments
$0
EBIT TTM
$-24,928,000
Pretax Income TTM
$-25,420,000
Interest Exp TTM
$492,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$980,000
EBITDA
$-36,238,000
Free Cash Flow
$-20,674,000
Enterprise Value
$94,089,992
Total Cash
$30,497,000
Total Debt
$610,000
Shares Out
51,212,833
Trailing EPS
$-0.72
Book Value
$1.45
ROE
-37.6%
ROA
-22.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jul 2025 | — | — | — | — | — | — | — |
| Jul 2024 | 637,000 | -102,627,000 | -34,410,000 | 96,832,000 | 10,574,000 | 82,185,000 | -7,802,000 |
| Jul 2023 | 279,000 | -15,043,000 | -1,876,000 | 98,829,000 | 2,200,000 | 100,293,000 | -10,886,000 |
| Jul 2022 | 410,000 | -60,477,000 | -124,658,000 | 118,320,000 | 21,114,000 | 100,515,000 | -26,079,000 |
TTM Snapshot
Revenues TTM
$980,000
NetIncome TTM
$-32,553,000
OpCashFlow TTM
—
Assets (Latest)
$91,990,000
Forward EPS
—
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $1.60 · call oi: 657 · put oi: 668
Expected Move to 2026-10-16:
±$0.93
(57.81%) —
implied range
$0.68 –
$2.53
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZYBT | Zhengye Biotechnology Holding Ltd | $81.99M | $1.73 | — |
| ACRV | Acrivon Therapeutics, Inc. | $81.85M | $1.91 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $81.26M | $1.52 | — |
| ZOMDF | Zomedica Corp. | $83.20M | $0.08 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $80.08M | $2.78 | — |
News headlines (Yahoo Finance, 1h cache)
Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
2026-10-04 06:01 · Yahoo
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
2026-10-01 13:49 · Yahoo
Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint
2026-09-30 13:49 · Yahoo
Rafael Holdings stock tumbles 25% as drug trial misses goal
2026-09-30 13:47 · Yahoo
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
2026-09-30 11:00 · Yahoo
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
2026-06-11 11:30 · Yahoo
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
2026-04-22 11:00 · Yahoo
Rafael Holdings Insider Ups Holding By 1,810% During Year
2026-04-28 14:26 · Yahoo
Israel said to eye US listing for major defense firms
2026-06-23 16:10 · Yahoo
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
2026-06-10 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.